Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
A restless night’s sleep is an all-to-common side effect of living with multiple myeloma (MM). Not only did I have trouble sleeping during my therapy but I continue to have trouble sleeping due to long-term side effects like my hemorrhagic cystitis (caused by cytoxan chemotherapy). Melatonin is an ideal multiple myeloma therapy.
My point is that living with MM, before, during or after active MM therapy can make sleep difficult. The first study linked below does not recommend melatonin for the MM survivor. The study gives a “on the other hand…”
Finally, my own experience over the past fifteen or so years is that I take melatonin (MEL) a couple of times a week. 300 micrograms. I find MEL helps me fall asleep faster and stay asleep longer.
I’ve tried taking MEL for several nights in a row and I’ve found that the benefits seem to dissipate. If I take MEL only, say, once every few days, the effects work better for me.
After years of MEL supplementation, my conclusion is that melatonin helps me sleep and may even help keep me in complete remission from my multiple myeloma.
For more information about nutritional supplementation for cancer as well as cancer side effects, scroll down the page, post a question or comment and I will reply ASAP.
Melatonin and Cancer Hallmarks.Talib WH et al. Molecules. (2018)
Melatonin for the prevention and treatment of cancer.Li Y et al. Oncotarget. (2017)
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.Reiter RJ et al. Int J Mol Sci. (2017)
“Melatonin (MEL), the main hormone produced by the pineal gland, seems to exert antineoplastic activity both in vitro and in vivo. Moreover, several studies reported increased melatonin blood levels in cancer patients.
Plasma melatonin concentrations were determined in 46 patients with multiple myeloma and in 31 age matched healthy subjects. Venous blood was drawn between 7.30 and 9.30 a.m. and melatonin was assayed using a commercially available radioimmunoassay.
The data were analysed by Student’s t test and results reported as mean values +/- standard deviation. The patients with multiple myeloma showed significantly higher mean melatonin serum levels than healthy subjects .
This behaviour could actually represent a phenomenon secondary to an altered endocrine-metabolic balance caused by an increased demand of the developing tumor. On the other hand, the increased melatonin secretion might be considered as a compensatory mechanism due to its antimitotic action and therefore as an effort to secrete substances capable of regulating neoplastic growth.”
“”Our data support the hypothesis that one night of not getting enough sleep in older adults activates important biological pathways that promote biological aging,” said lead author Judith Carroll, PhD…”
The study group comprised 29 community-dwelling older adults. They were age 61-86 years and 48 percent were male. Participants underwent an experimental partial sleep deprivation protocol over four nights, including adaptation, an uninterrupted night of sleep, partial sleep deprivation (restricted 3 a.m. – 7 a.m.) and another uninterrupted night of sleep (recovery). Blood samples were obtained each morning to assess PBMC gene expression using Illumina HT-12 arrays.”